Literature DB >> 32077606

EASL clinical practice guidelines for the management of occupational liver diseases.

Massimo Colombo1.   

Abstract

The Clinical Practice Guidelines (CPG) on Occupational Liver Diseases (OLD) of the European Association for the Study of the Liver (EASL) have been developed to increase awareness, recognition and improve management of patients with OLD. Indeed, although workplace exposure has been associated with virtually the entire spectrum of acute and chronic liver diseases, data on the epidemiology of OLD are scarce. These diseases may be a result of high-level accidental exposure or prolonged lower level exposure to a variety of chemicals including solvents, pesticides, metals and other agents. While acute liver diseases related to OLD are uncommon and easily recognized, chronic liver diseases are relatively more frequent but often overlooked because of their asymptomatic course and an insidious onset which is often accompanied by comorbidities. Because of the absence of data in observational studies and meta-analyses or systematic reviews, the evidence and recommendations in these guidelines have been graded according to the Oxford Centre for Evidence-based Medicine, which assesses evidence according to diagnostic, prevalence, aetiological, prognostic or preventive categories. They can still generate grades of recommendation even when the evidence is inconclusive.
© 2020 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  drug-induced liver injury; hepatocellular carcinoma; liver angiosarcoma; occupational liver disease; toxicant-associated steato hepatitis

Mesh:

Substances:

Year:  2020        PMID: 32077606     DOI: 10.1111/liv.14349

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  4 in total

1.  An Optimal Ablative Margin of Small Single Hepatocellular Carcinoma Treated with Image-Guided Percutaneous Thermal Ablation and Local Recurrence Prediction Base on the Ablative Margin: A Multicenter Study.

Authors:  Feng-Yao Li; Jian-Guo Li; Song-Song Wu; Huo-Lin Ye; Xu-Qi He; Qing-Jing Zeng; Rong-Qin Zheng; Chao An; Kai Li
Journal:  J Hepatocell Carcinoma       Date:  2021-11-15

2.  Detection of hepatocellular carcinoma in a population at risk: iodine-enhanced multidetector CT and/or gadoxetic acid-enhanced 3.0 T MRI.

Authors:  Lan Qiong; Zhao Jie; Zheng Zhong; Sheng Wen; Zhao Jun; Lu Liping; Cheng Jinkui
Journal:  BMJ Open       Date:  2022-02-17       Impact factor: 2.692

3.  Non-contrast Magnetic Resonance Imaging versus the Multiphase Computed Tomography with Respect to the Asia-Pacific Clinical Practice Guidelines: A Diagnostic Performance Study for Liver Cancer.

Authors:  Yang Wei; Liu Haifen; Li Xiang; Zhang Shutong; Chen Yanhao; Wang Xiang
Journal:  Turk J Gastroenterol       Date:  2021-03       Impact factor: 1.852

4.  Change in the Recurrence Pattern and Predictors over Time after Complete Cure of Hepatocellular Carcinoma.

Authors:  Han Ah Lee; Young-Sun Lee; Beom Kyung Kim; Young Kul Jung; Seung Up Kim; Jun Yong Park; Ji Hoon Kim; Hyunggin An; Do Young Kim; Hyung Joon Yim; Sang Hoon Ahn; Jong Eun Yeon; Kwan Soo Byun; Kwang-Hyub Han; Soon Ho Um; Yeon Seok Seo
Journal:  Gut Liver       Date:  2021-05-15       Impact factor: 4.519

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.